Publication: Capecitabine-induced bilateral ectropion: a rare ocular manifestation requiring surgical intervention
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Müftüoğlu, Orkun | |
dc.contributor.kuauthor | Özmen, Selahattin | |
dc.contributor.kuauthor | Sezgin, Billur | |
dc.contributor.kuauthor | Taş, Ayşe Yıldız | |
dc.contributor.kuauthor | Tatar, Sedat | |
dc.contributor.kuauthor | Yalçın, Can Ege | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T13:13:12Z | |
dc.date.issued | 2018 | |
dc.description.abstract | It has been established that many chemotherapeutic agents are associated with a variety of ocular side effects. As an antineoplastic agent, 5-fluorouracil (5-FU) is the chemotherapeutic agent that is frequently linked with cicatricial ectropion. Capecitabine is a prodrug of 5-FU and has a more favorable side effect profile than 5-FU. Frequent side effects of capecitabine include gastrointestinal events and hand-foot-mouth syndrome; cicatricial ectropion is rather uncommon. Enzyme deficiencies affecting the capecitabine metabolism have been reported to be associated with exaggerated generalized systemic and cutaneous side effects; however, there are no cases in the literature reporting capecitabine-induced isolated bilateral-progressive ectropion. Although cessation of the agent is frequently sufficient for the treatment of ectropion, close follow-up is indicated in such patients as permanent damage may occur if the problem is left untreated. We report a case of capecitabine-induced bilateral cicatricial ectropion refractory to treatment cessation, ultimately requiring surgical treatment. | |
dc.description.fulltext | YES | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 2 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.version | Publisher version | |
dc.description.volume | 16 | |
dc.identifier.doi | 10.4103/JCAS.JCAS_5_18 | |
dc.identifier.eissn | 0974-5157 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR00911 | |
dc.identifier.issn | 0974-2077 | |
dc.identifier.quartile | N/A | |
dc.identifier.scopus | 2-s2.0-85061306554 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/2930 | |
dc.keywords | Cystoid macular | |
dc.keywords | 5-fluorouracil | |
dc.keywords | Capecitabine | |
dc.keywords | Ectropion | |
dc.keywords | Skin grafting | |
dc.language.iso | eng | |
dc.publisher | Medknow Publications | |
dc.relation.ispartof | Journal of Cutaneous and Aesthetic Surgery | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8157 | |
dc.subject | Medicine | |
dc.subject | Macular edema | |
dc.subject | Eye | |
dc.title | Capecitabine-induced bilateral ectropion: a rare ocular manifestation requiring surgical intervention | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Tatar, Sedat | |
local.contributor.kuauthor | Yalçın, Can Ege | |
local.contributor.kuauthor | Sezgin, Billur | |
local.contributor.kuauthor | Taş, Ayşe Yıldız | |
local.contributor.kuauthor | Müftüoğlu, Orkun | |
local.contributor.kuauthor | Özmen, Selahattin | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
Files
Original bundle
1 - 1 of 1